The Emerging Role of Neuropeptides in Parkinson’s Disease

Yanan Zheng¹, Linlin Zhang¹, Junxia Xie¹,² and Limin Shi¹,²*

¹ Department of Physiology, Shandong Provincial Key Laboratory of Pathogenesis and Prevention of Neurological Disorders, School of Basic Medicine, Qingdao University, Qingdao, China, ² Institute of Brain Science and Disease, Qingdao University, Qingdao, China

Parkinson’s disease (PD), the second most common age-related neurodegenerative disease, results from the loss of dopamine neurons in the substantia nigra. This disease is characterized by cardinal non-motor and motor symptoms. Several studies have demonstrated that neuropeptides, such as ghrelin, neuropeptide Y, pituitary adenylate cyclase-activating polypeptide, substance P, and neurotensin, are related to the onset of PD. This review mainly describes the changes in these neuropeptides and their receptors in the substantia nigra-striatum system as well as the other PD-related brain regions. Based on several in vitro and in vivo studies, most neuropeptides play a significant neuroprotective role in PD by preventing caspase-3 activation, decreasing mitochondrial-related oxidative stress, increasing mitochondrial biogenesis, inhibiting microglial activation, and anti-autophagic activity. Thus, neuropeptides may provide a new strategy for PD therapy.

Keywords: Parkinson’s disease, neuropeptides, ghrelin, neuropeptide Y, pituitary adenylate cyclase-activating polypeptide, substance P, neurotensin

INTRODUCTION

Parkinson’s disease (PD) is a progressive age-related neurodegenerative disease that results in cardinal motor symptoms, such as bradykinesia, muscle rigidity, and static tremor. The neuropathogenesis of PD is characterized by selective lesions of dopamine (DA) neurons in the mesencephalic substantia nigra (SN)-striatum pathway and the formation of Lewy bodies in the remaining neurons (Obeso et al., 2000). DA replacement therapies (L-DOPA) can relieve these symptoms; however, their prolonged use often causes severe side effects, marked by involuntary muscle movements.

Neuropeptides are small protein-like molecules that are generated and secreted, though not solely, by neurons in the central and peripheral nervous systems (Carniglia et al., 2017). Most neuropeptides act on G-protein coupled receptors (GPCRs). Peptide-GPCRs signals are known to be involved in various brain functions, such as glucose metabolism, learning and memory, stress and anxiety, food intake, reward, sleep and wakefulness, and neuroprotection (Jiao et al., 2017; Chen et al., 2018). Recently, several neuropeptides such as ghrelin, neuropeptide Y (NPY), pituitary adenylate cyclase-activating polypeptide (PACAP), substance P (SP), and neurotensin have been shown to play neuroprotective roles in PD both in vivo and in vitro (Wang et al., 2015b; Bayliss et al., 2016a; Maasz et al., 2017; Shi et al., 2017; Lazarova et al., 2018; Li et al., 2019). In this review, we discuss the relationship between these neuropeptides and PD and their underlying mechanisms. Additionally, patients with PD exhibit aberrant expression of central and peripheral neuropeptides.
The changes in PD-related neuropeptides levels are also discussed, which might provide a possible basis for the development of a putative biomarker for the diagnosis and management of PD.

**GHRELIN**

Ghrelin, a 28-amino-acid protein, acts as an exclusive endogenous ligand for the growth hormone secretagogue receptor 1a (GHS-R1a). It is mainly secreted in the stomach and is expressed in the pituitary, the internuclear space between the arcuate nucleus, the lateral hypothalamus, the dorsomedial nucleus, the ventromedial nucleus, the ependymal layer of the third ventricle, and the paraventricular nucleus (Kojima et al., 1999; Cowley et al., 2003; Hou et al., 2006). Two circulating forms of ghrelin exist in the plasma: acylated and deacylated ghrelin (Bayliss et al., 2016a). Acyl-ghrelin is believed to activate the GHS-R1a to exert biological effects (Delhanty et al., 2012). Previous studies have determined that the acylated form is responsible for neuroprotection in PD (Bayliss et al., 2016a; Wagner et al., 2017).

Downregulated levels of ghrelin and GHS-R1a are known to be closely related to the pathogenesis of PD. In patients with PD, the fasting levels of both active (acylated form) and total ghrelin were downregulated, with a relatively substantial decrease in the active form, compared with healthy controls (Table 1; Song et al., 2017). The genetic ablation of GHSR was found to aggravate the decrease in nigral DA neurons and lower striatal DA levels in PD animal models, which could be reversed by selectively reactivating GHSCR in catecholaminergic neurons (Andrews et al., 2009). Additionally, other studies revealed that either an intracerebroventricular injection or microinjection of the selective GHS-R1a antagonist [D-Lys3]-GHRP6 into the SN of normal mice could produce PD-like dysfunction in motor coordination (Suda et al., 2018).

Our group was the first to report the neuroprotective effects of ghrelin in an 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD model (Jiang et al., 2008), which were later confirmed by other studies (Andrews et al., 2009; Moon et al., 2009; Yu et al., 2016). Ghrelin counteracted rotenone-induced cell loss (Yu et al., 2016; Liu et al., 2018), improved the impaired performance of rota-rod in the mouse MPTP-induced model of PD (Moon et al., 2009), and mediated the neuroprotective effects of caloric restriction (Bayliss et al., 2016b). Additionally, ghrelin has been shown to electrically activate DA neurons via the inhibition of KCNQ and A-type potassium channels and upregulate HCN channels to improve the inhibition neurons via the inhibition of KCNQ and A-type potassium channels (Kojima et al., 1999; Cowley et al., 2003; Hou et al., 2006). Two circulating forms of ghrelin exist in the plasma: acylated and deacylated ghrelin (Bayliss et al., 2016a). Acyl-ghrelin is believed to activate the GHS-R1a to exert biological effects (Delhanty et al., 2012). Previous studies have determined that the acylated form is responsible for neuroprotection in PD (Bayliss et al., 2016a; Wagner et al., 2017).

Downregulated levels of ghrelin and GHS-R1a are known to be closely related to the pathogenesis of PD. In patients with PD, the fasting levels of both active (acylated form) and total ghrelin were downregulated, with a relatively substantial decrease in the active form, compared with healthy controls (Table 1; Song et al., 2017). The genetic ablation of GHSCR was found to aggravate the decrease in nigral DA neurons and lower striatal DA levels in PD animal models, which could be reversed by selectively reactivating GHSCR in catecholaminergic neurons (Andrews et al., 2009). Additionally, other studies revealed that either an intracerebroventricular injection or microinjection of the selective GHS-R1a antagonist [D-Lys3]-GHRP6 into the SN of normal mice could produce PD-like dysfunction in motor coordination (Suda et al., 2018).

Our group was the first to report the neuroprotective effects of ghrelin in an 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD model (Jiang et al., 2008), which were later confirmed by other studies (Andrews et al., 2009; Moon et al., 2009; Yu et al., 2016). Ghrelin counteracted rotenone-induced cell loss (Yu et al., 2016; Liu et al., 2018), improved the impaired performance of rota-rod in the mouse MPTP-induced model of PD (Moon et al., 2009), and mediated the neuroprotective effects of caloric restriction (Bayliss et al., 2016b). Additionally, ghrelin has been shown to electrically activate DA neurons via the inhibition of KCNQ and A-type potassium channels and upregulate HCN channels to improve the inhibition of MPP⁺ on the excitability of DA neurons (Shi et al., 2013; Chang et al., 2020; Xue et al., 2020). The most recent research showed that ghrelin enhanced the proliferation, migration, and differentiation of midbrain neural stem cells via the Wnt/β-catenin pathway, which proposed a novel possibility that ghrelin might be clinically valuable for the treatment of PD (Gong et al., 2020). Additionally, chronic treatment with ghrelin agonist HM01 was found to improve 6-OHDA lesion-induced nonmotor symptoms in a rat model of PD, including alterations in body weight, fecal weight, food intake, and water consumption (Minalyan et al., 2019). Ghrelin analog, Dpr3ghr, also protected SH-SY5Y cells from methylglyoxal-induced neurotoxicity and apoptosis (Popelova et al., 2018).

The mechanisms underlying the neuroprotective effects of ghrelin are complex (Figure 1; Morgan et al., 2018). The first study based on a sub-acute MPTP-induced mouse model of PD demonstrated that ghrelin-mediated neuroprotection might be related to a reduction in caspase-3-mediated apoptosis via the regulation of gene expression of Bcl-2 and Bax in the DA neurons in SN (Jiang et al., 2008). Another study showed that ghrelin antagonized rotenone/MPP⁺-induced neurotoxicity in MES23.5 cells and retinal ganglion cells by inhibiting the activity of mitochondrial respiratory chain complex I, eliminating reactive oxygen species (ROS) synthesis, stabilizing mitochondrial transmembrane potential (Δψm), and inhibiting caspase-3 activation (Dong et al., 2009; Yu et al., 2016; Liu et al., 2018).

Ghrelin-induced neuroprotection is dependent on mitochondrial-related oxidative stress and mitochondrial biogenesis. Andrews et al. (2009) proposed that ghrelin-induced uncoupling protein 2 (UCP2)-dependent alterations in mitochondrial respiration and a bioenergetics status provision, which might make the DA neurons more resistant toward cellular stress. Liu et al. (2010) demonstrated that ghrelin exerted its antioxidant effects by increasing the activity of Cu-Zn superoxide dismutase (CuZn-SOD) and catalase (CAT), decreasing the concentration of malonaldehyde (MDA), and inhibiting NF-κB translocation. Another study indicated that ghrelin-induced neuroprotection was dependent on the activation of AMPK (S' adenosine monophosphate-activated protein kinase) and enhanced mitophagy in DA neurons (Bayliss and Andrews, 2013). Ghrelin could exert its neuroprotective effects by inhibiting the activation of microglia and the subsequent release of IL-1β and TNF-α in an MPTP-induced mouse model of PD (Moon et al., 2009).

**NEUROPEPTIDE Y**

Neuropeptide Y (NPY), a 36-amino-acid peptide, was first isolated in 1982 from the porcine brain (Tatemoto, 1982). NPY is unequally distributed across the brain, with higher levels in the hypothalamus, amygdala, hippocampus, and striatum (de Quidt and Emson, 1986). NPY receptors are classified as GPCRs, five of which have already been cloned from mammals: Y1, Y2, Y4, Y5, and Y6 receptors (Li et al., 2019). The Y1 receptor mRNA is distributed in all layers of most limbic and neocortical regions, striatum, caudate, putamen, and nucleus accumbens (Caberlotto et al., 1997, 2000). The Y2 receptor mRNA is found in different areas, including the cerebral cortex, striatum, the hippocampal formation, and the nucleus accumbens (Caberlotto et al., 1997, 2000). The Y4 receptor mRNA is primarily found in the thalamus, subthalamic nucleus, hypothalamus, amygdala, SN, and lesser expression in the corpus callosum, caudate nucleus, and hippocampus (Yan et al., 1996). High levels of Y5 receptor mRNA are found in the SN, hypothalamus, and amygdala.
| Neuropeptides/Receptors     | Changes | Biological sample                                      | State of disease                      | References                  |
|----------------------------|---------|------------------------------------------------------|---------------------------------------|-----------------------------|
|                             |         |                                                      |                                        |                             |
| Ghrelin                    | ↓       | Plasma                                               | PD patients                           | Song et al., 2017            |
| Neuropeptide Y             | ↓       | Adrenal medullary tissues                            | PD patients                           | Stoddard et al., 1991       |
| Neuropeptide Y             | ↓       | Cerebrospinal fluid                                  | PD patients                           | Martignoni et al., 1992     |
| Neuropeptide Y mRNA        | ↑       | Caudate nucleus, putamen and nucleus accumbens      | PD patients                           | Cannizzaro et al., 2003     |
| Neuropeptide Y positive cells | ↓     | Caudate nucleus and putamen                          | X-linked dystonia-parkinsonism patients| Goto et al., 2013           |
| Neuropeptide Y             | ↑       | Striatum                                             | MPTP-induced mouse model              | Obuchowicz et al., 2003     |
| PAC1 receptor              | ↓       | Caudate nucleus, putamen, and globus pallidus       | MPTP-induced macaque models           | Feher et al., 2018          |
| Substance P                | ↓       | SN and the external segment of the globus pallidus   | PD patients                           | Mauborgne et al., 1983      |
| Substance P                | ↓       | Saliva                                               | PD patients                           | Schroder et al., 2019       |
| Substance P                | ↑       | SN and striatum                                      | 6-OHDA-induced PD rat model (3–4 weeks after lesion) | Lindefors et al., 1989      |
| Substance P                | ↑       | SN                                                   | 6-OHDA-induced PD rat models (3–21 days after lesion) | Thornton and Vink, 2012     |
| Neurotensin                | ↑       | SN                                                   | PD patients                           | Fernandez et al., 1995, 1996 |
| Neurotensin                | ↑       | Plasma                                               | PD patients                           | Schimpff et al., 2001       |
| NT receptors mRNA          | ↓       | the ventral tier of the substantia nigra             | PD patients                           | Yamada et al., 1996         |
| NT receptors               | ↓       | Putamen and globus pallidus                          | PD patients                           | Uhl et al., 1984; Chinaglia et al., 1990; Fernandez et al., 1994 |
FIGURE 1 | Potential neuroprotective effects of ghrelin in PD. Ghrelin and its analog produce neuroprotective effects against MPTP/MPP⁺ and rotenone-induced toxicity via anti-apoptosis, anti-oxidative stress, and anti-inflammation. By interacting with GHS-R1α, ghrelin inhibits neuronal apoptosis via increasing Bcl-2/Bax ratio and reducing Caspase-3 activation. Ghrelin enhances the antioxidant enzyme CAT and CuZn-SOD expression, and inhibits the lipid peroxidation and ROS production. The upregulation of UCP-2 caused by ghrelin could also buffer ROS production, as well as promote mitochondrial biogenesis. Additionally, ghrelin prevents inflammatory microglial activation and enhances neuronal excitability by inhibiting voltage-gated potassium channels. Ghrelin also has the capability to enhance the proliferation, migration, and differentiation of midbrain neural stem cells via the Wnt/β-catenin pathway. Furthermore, ghrelin is proposed to provide neuroprotective effects via AMPK activation and enhanced mitophagy to ultimately enhance mitochondrial bioenergetics. GHS-R1α, growth hormone secretagogue receptor-1α; UCP2, uncoupling protein 2; MDA, malonaldehyde; ROS, reactive oxygen species; CuZn-SOD, CuZn superoxide dismutase; CAT, catalase; AMPK, 5′adenosine monophosphate-activated protein kinase; IL-1β, interleukin-1β; TNF-α, tumor necrosis factor-α; DA, dopamine. The red line is inhibition and the black line is activation.

(Nichol et al., 1999). The Y6 receptor mRNA is only functionally expressed in the rabbit and mouse and is not expressed in the rat (Starback et al., 2000).

Several animal and human studies have detected changes in NPY levels. Stoddard et al. (1991) reported lower NPY levels in the adrenal medullary tissues in PD patients. Later, Martignoni et al. (1992) measured NPY-immunoreactivity (NPY-ir) levels in the cerebrospinal fluid (CSF) of 10 patients with PD and found them lower than that in healthy individuals, which indicated a reduction in NPY release or increase in NPY turnover. Moreover, the number of NPY mRNA positive cells was markedly increased in the caudate nucleus, putamen, and nucleus accumbens in the post-mortem brain specimens of patients with PD (Cannizzaro et al., 2003). Additionally, studies have found a decrease in NPY-positive cells and a significant loss of nerve fibers in the putamen and caudate nucleus in X-linked dystonia-parkinsonism patients (Goto et al., 2013). In the subventricular zone, these patients also lacked NPY labeling, along with a significant loss of progenitor cells that expressed proliferating cell nuclear antigen (Goto et al., 2013). Svenningsson et al. (2017) recently reported higher levels of NPY in CSF of PD patients with comorbid depression compared with those with major depressive disorder. In animal models of PD, the degeneration of the nigrostriatal DA pathway caused a remarkable increase in NPY-expressing cells in the striatum (Kerkerian et al., 1986, 1988; Obuchowicz et al., 2003). All these results supported an association between NPY and PD.

Neuropeptide Y has been demonstrated to exert its potent neuroprotective effects via a variety of pathways related to PD (Figure 2). Decressac et al. (2012) first reported that NPY exerted its neuroprotective effects in both in vitro and in vivo 6-OHDA-induced models of PD. Using pharmacological antagonist and mice knockout for Y2 receptors, it was shown that NPY exerted its neuroprotective effects by acting on DA cells and terminals via the Y2 receptor, which induced the activation of the ERK and Akt pathways (Decressac et al., 2012). NPY also inhibited the activation of microglia in SN and striatum of 6-OHDA rats, which mediated the anti-inflammatory effect of NPY in PD (Pain et al., 2019). Another study confirmed the inhibitory effect of NPY on LPS-stimulated NO synthesis and IL-1β secretion in the microglia (Ferreira et al., 2010). Additionally, several studies have
FIGURE 2 | Potential neuroprotective effects of NPY in PD. NPY may be exerting its neuroprotective effect by directly acting on DA cells via Y2 receptor. NPY activates the ERK and Akt pathways, and inhibits ER stress–induced neuronal cell death by activating the PI3K-XBP1s-Gip78/BiP pathway. NPY treatment also inhibits apoptosis by suppressing the activation of caspase-3 and -4. Additionally, NPY prevents the activation of microglia and the production of NO and IL-1β. NPY, neuropeptide Y; ERK1/2, extracellular signal-regulated kinase 1/2; ER, endoplasmic reticulum; NO, nitric oxide; IL-1β, interleukin-1β. The red line is inhibition and the black line is activation.

demonstrated higher levels of endoplasmic reticulum (ER) stress in common neurodegenerative diseases, such as Parkinson’s, Huntington’s, and Alzheimer’s diseases (Matus et al., 2011). A recent study found that NPY exerted a protective effect against cell death in ER stress–induced neurons by activating the PI3K-XBP1s-induced Gip78/BiP pathway (Lee et al., 2018). NPY treatment also suppressed the activation of caspase-3 and caspase-4 in the ER stress response pathway (Lee et al., 2018).

It was hypothesized that the neuroprotective mechanism of NPY was probably related to the brain-derived neurotrophic factor (BDNF), which is a neurotrophin that promotes neuronal survival and differentiation (Sendtner et al., 1992). Reduced expression of BDNF has been postulated to cause the loss of nigral DA neurons in PD (Sendtner et al., 1992; Fumagalli et al., 2006). Until now, there are no published reports on the possible relationship between NPY and PD-related BDNF expression. However, in mouse models of Machado–Joseph disease, an inherited neurodegenerative disorder, NPY overexpression was found to alleviate motor deficits and neuropathology by increasing BDNF expression and reducing neuroinflammation (Duarte-Neves et al., 2015). Future studies need to explore the possible effects of NPY on BDNF expression in PD.

PACAP

Pituitary adenylate cyclase-activating polypeptide belongs to the superfamily of glucagon/secretin/vasoactive intestinal polypeptide (VIP); it was first isolated from an ovine hypothalamus (Miyata et al., 1989). PACAP is widely expressed, particularly at high concentrations, in the hypothalamus, nucleus accumbens, bed nucleus of the stria terminalis, and SN in the mammalian brain (Chung et al., 2005; Vaudry et al., 2009). Additionally, the PACAP genes had >2.0-fold elevation of mRNA levels in ventral tegmental area (VTA) compared with SN DA neurons (Chung et al., 2005). Exposing α-synuclein overexpressing PC12 cells and rat primary ventral mesencephalic cultures to PACAP decreased vulnerability of both cell types to MPP+, suggesting that the upregulation of PACAP gene in VTA could be one of the factors responsible for the altered vulnerability (Chung et al., 2005).

Pituitary adenylate cyclase-activating polypeptide receptors, which belong to the family of GPCRs, include PAC1, VPAC1, and VPAC2 receptors. The mRNA encoding the PACAP receptors has been identified in the SN (Hashimoto et al., 1996). Additionally, a significantly reduced PAC1 receptor immunosignal was detected in the putamen, caudate nucleus, and internal and external parts of the globus pallidus in MPTP-induced macaque models of PD (Wang et al., 2005; Feher et al., 2018).

Several studies have shown the neuroprotective impact of PACAP in different PD models (Reglodi et al., 2011, 2017). PACAP was found to attenuate 6-OHDA-induced loss of DA neurons, improve behavioral deficits (Reglodi et al., 2004a), reduce severe acute hypokinesia (Reglodi et al., 2004b), and attenuate the decrease in DA levels (Maasz et al., 2017). PACAP could prevent the MPTP-induced dysregulation of protein...
synthesis and attenuate cognitive decline (Deguil et al., 2010). In rotenone-induced PD cell models, PACAP was found to decrease cellular apoptosis and facilitate the transformation of cell apoptosis from late stage to early stage (Wang et al., 2005). In SH-SY5Y cells, PACAP protected against salsolinol-induced toxicity by attenuating apoptosis and the associated chemical changes (Brown et al., 2013). In a prostaglandin J2 (PGJ2)-induced mouse model of PD, PACAP27 reduced the loss of DA neurons and motor deficits (Shivers et al., 2014).

It has been shown that PACAP exerts its neuroprotective effects on PD via multiple mechanisms (Figure 3). First, PACAP-induced neuroprotection was associated with its anti-inflammatory effects. The pre-treatment of SH-SY5Y cells with PACAP (1–38) resulted in a dose-dependent attenuation of toxicity caused by the inflammatory mediators (Brown et al., 2014). Second, PACAP exhibited anti-autophagic properties. In the MPTP-induced models, PACAP reduced the autophagic activity by producing LC3II and modulating p62 protein levels (Lamine-Ajili et al., 2016). Third, Wang et al., 2005 found that the protective role of PACAP against rotenone-induced cell death was inhibited by the administration of PKA, ERK, and p38 inhibitors. Thus, PACAP exerted its neuroprotective effects by activating PKA signaling pathway as well as the downstream ERK and p38 MAPK signals (Wang et al., 2005). Fourth, this neuroprotective effect was found to be correlated to a balance between DA-ACh systems in the basal ganglia neuronal pathway. In the MPTP-induced PD mouse model, intravenous injection of PACAP27 offered neuroprotective effects by changing the cholinergic and dopaminergic neurotransmission, which were associated with the increase of the D2 receptors activity and KATP subunits expression in the striatum (Wang et al., 2008). Fifth, PACAP or its receptor agonists attenuated the salsolinol-induced toxicity of SH-SY5Y cells by enhancing the expression of BDNF and its signal transduction protein, p-CREB, and inhibiting the expression of caspase-3 (Brown et al., 2013). Apart from these mechanisms, PACAP-induced neuroprotection was probably associated with microglia. PACAP could attenuate LPS-induced activation of microglia and the consequent NO synthesis and TNF-α secretion (Yang et al., 2006). However, Shivers et al., 2014 reported that PACAP27 was unable to prevent microglial activation in the PGJ2-induced mouse model of PD (Shivers et al., 2014). Future studies need to explore the precise role of PACAP in microglial activation in PD.

Vasoactive intestinal polypeptides is a related peptide of PACAP which was first isolated from pig small intestine (Said and Mutt, 1970). Recent studies have found that it also has the similar neuroprotective effects as PACAP (Korkmaz and Tunçel, 2018). VIP prevented the MPTP-induced loss of DA neurons and nerve fibers in the nigrostriatal pathway by inhibiting of proinflammatory toxic molecules (i.e., TNF-α, ROS, NO, and IL-1β) (Delgado and Ganea, 2003). In 6-OHDA-induced PD rats models, VIP was found to reverse the rotational deficits, renovate myelin sheet (Tunçel et al., 2005), preserve corpus striatum neurons via producing nerve growth factor by brain mast cells (Korkmaz et al., 2010), exert the potential of anti-apoptosis and anti-oxidation to protect corpus striatum neurons by reducing DNA fragmentation and lipid peroxidation (Tunçel et al., 2012).

Interestingly, Yu et al. (2020) found that VIP-TAT, which was similar to PACAP with two-dimensional structure, could increase more traversing potency than VIP to exert effective neuroprotective effect in the MPTP-induced PD mouse models.

**SUBSTANCE P**

Substance P (SP), an undecapeptide encoding the tachykinin 1 (TAC1) gene, belongs to the tachykinin family. It is known to exert multiple biological roles by acting on three different types of GPCRs called NK1, NK2, and NK3 receptors (Pennefather et al., 2004). SP is widely distributed throughout the central and peripheral nervous systems. High levels of SP are found in the basal ganglia, where the SN showed the highest levels (Kanazawa and Jessell, 1976).

In the 1980s, Mauborgne et al. (1983) found a significant decrease in SP-like immunoreactivity within the SN and the external segment of the globus pallidus in parkinsonian brains, which was later confirmed by other studies (Tenovuo et al., 1984; Sivam, 1991; De Ceballos and Lopez-Lozano, 1999). Compared with PD patients with normal pharyngeal swallowing function, significantly lower levels of SP in the saliva were found in those with pharyngeal dysphagia (Schröder et al., 2019). Other studies observed SP variations in 6-OHDA-induced PD rat models. An early study showed that the DA degeneration decreased the concentration of SP in both SN and striatum (3–4 weeks after 6-OHDA lesion) (Lindefors et al., 1989). However, Thornton and Vink (2012) observed elevated nigral SP levels from days 3 to 21 after 6-OHDA treatment. It appeared that the 6-OHDA lesion resulted in an increase in SP levels initially followed by a decrease.

Until now, the effect of SP in the treatment of PD remains controversial. Wang et al. (2015b) found that SP protected MES23.5 cells from MPP⁺-induced cytotoxicity by decreasing calcium influx, regulating Δψₐₘ, and modulating ROS synthesis and caspase-3 activation. However, other studies have shown that SP exacerbates dopaminergic cell death. For example, in the 6-OHDA-induced model of PD, the administration of additional SP accelerated disease progression and exacerbated dopaminergic cell death, with animals displaying extensive motor deficits (Thornton and Vink, 2012). Exogenous SP activated microglia, followed by potentiating LPS- or MPP⁺-induced toxicity in primary dopaminergic cell cultures; the absence of endogenous SP in TAC1⁻/⁻ mice made them more resistant to neurotoxicity-induced dopaminergic neurodegeneration (Wang et al., 2014).

Similarly, both SP receptor agonists and antagonists demonstrated neuroprotective effects in PD. Peptide [(Pyr6, Pro9)-SP (6–11)], the NK1 receptor agonist, ameliorated dopaminergic neurodegeneration and motor deficits via Akt/PKB signaling pathway in 6-OHDA-lesioned rats (Chu et al., 2011). Additionally, sentkide, the NK3 receptor agonist, restored the temporal order memory in the animals (Chao et al., 2015). However, intracerebroventricular administration of the NK1 receptor antagonist L-733,060 or N-acetyl-L-tryptophan (NAT) also attenuated 6-OHDA-mediated cell death and resulted in a significant improvement in motor function (Thornton and Vink, 2012). NAT and another NK1 receptor antagonist, LY303870,
FIGURE 3 | Potential neuroprotective effects of PACAP in PD. Both animal and cell models of PD show that PACAP produces neuroprotective effects against MPTP/MPP+, rotenone and salsolinol-induced toxicity via anti-autophagy, anti-inflammatory, and anti-apoptosis. PACAP diminishes MPP+ -induced accumulation of LC3II and reduction of p62 protein. PACAP antagonizes salsolinol and rotenone-induced cell apoptosis by inhibiting the caspase-3 activity, which could be blocked by the administration of PKA, ERK, and p38 inhibitors. PACAP protects against inflammatory-mediated toxicity by enhancement of BDNF and its signal transduction protein p-CREB. Additionally, PACAP attenuates LPS-induced activation of microglia and the consequent NO synthesis and TNF-α secretion. PACAP also leads to the increase of D2 receptors activity and KATP subunits expression in the striatum, which results in the decrease of ACh secreting and finally regulates the balance between DA-ACh systems. PACAP, pituitary adenylate cyclase-activating polypeptide; PACAPR, pituitary adenylate cyclase-activating polypeptide receptors; LPS, lipopolysaccharide; NO, nitric oxide; TNF-α, tumor necrosis factor-α; MPP+, methyl-phenylpyridinium; p-CREB, phosphorylated cyclic adenosine monophosphate response element binding protein; BDNF, brain-derived neurotrophic factor; PKA, protein kinase A; ERK, extracellular signal-regulated kinase; SN, substantia nigra. The red line is inhibition and the black line is activation.

Reduced L-DOPA-induced dyskinesia without affecting the therapeutic role of L-DOPA in PD rats (Thornton et al., 2014; Yang et al., 2015).

Microglia mimics the role of macrophages in the brain; they are the primary form of active immune defense in the CNS. The substantia nigra pars compacta (SNc) contains a higher density of microglia than the surrounding brain regions (Kim et al., 2000). Recent findings have shown that SP might be partly responsible for the high density of microglia. Mice deficient in endogenous SP (TAC1−/−) or NK1R (NK1R−/−) showed a significant reduction in nigral microglial density (Wang et al., 2015a). Additionally, Wang et al. (2015a) illustrated that SP attracted microglia through a NK1R/PKCδ/NADPH oxidase pathway-dependent manner.

NEUROTENSIN

Neurotensin (NT), a 13-amino-acid peptide, was originally isolated from the bovine hypothalamus (Carraway and Leeman, 1973). It is closely involved in the dopaminergic system. Histological studies from rat brain have shown that abundant NT-containing fibers are found in DA-rich areas such as the ventral tegmental area and SN (Jomphe et al., 2006). Clinical research has shown a two-fold increase in NT concentration in the SN in the brain tissue specimens from patients with PD (Fernandez et al., 1995, 1996). The plasma NT concentration was also higher in drug-free PD patients compared with healthy controls and L-DOPA-treated subjects (Schimpff et al., 2001).

There are three subtypes of NT receptors, including NTS1, NTS2, and NTS3/sortilin-receptor (Vincent et al., 1999). High levels of NT receptor mRNA were found in rat brain DA neurons of the ventral tegmental area and SN (Yamada et al., 1995). However, in PD brain tissues, the ventral tier of the substantia nigra, very low levels or no expression of mRNA for NT receptors were found (Yamada et al., 1995). NT receptors levels were also markedly reduced in the putamen and globus pallidus of patients with PD (Uhl et al., 1984; Chinaglia et al., 1990; Fernandez et al., 1994).

Previous studies have shown that both NT and NT analogs exert neuroprotective effects in animal models of PD. Intracerebroventricular administration of NT8-13 and [D-Tyr11]-NT attenuated 6-OHDA-induced muscle rigidity and
tremors (Rivest et al., 1991). Recent findings also demonstrated that two new NT analogs, NT2 and NT4, could significantly decrease the number of apomorphine-induced rotations, enhance DA release in the striatum, and improve learning and memory (Lazarova et al., 2018). However, according to Antonelli et al. (2007) NT increased the degeneration of cortical neurons and dopaminergic mesencephalic neurons by enhancing glutamate-induced neurotoxicity by increasing intracellular calcium and/or the amplification of the NMDA-mediated glutamate signaling. Further studies are required to clarify the possible role of NT in PD and dopamine systems.

CONCLUSION

Here, we provided an overview of the recent studies on the role of neuropeptides, including ghrelin, NPY, PACAP, SP, and NT, in PD. Altered expressions of these neuropeptides and their receptors were found in PD-related regions, especially the SN-striatum pathway. Most neuropeptides exhibited neuroprotective effects against the selective lesion of DA neurons by inhibiting caspase-3 activation, attenuating mitochondria-related oxidative stress, inhibiting microglial activation, anti-inflammation, and anti-autophagic activity. Moreover, peptide analogs and receptor agonists or antagonists were also used to protect against neurotoxin-elicited nigrostriatal DA neuron damage and motor and non-motor deficits, providing a potential approach for the treatment of PD. Most neuropeptides could cross the blood-brain barrier (BBB) to play a neuroprotective role, such as ghrelin (Banks et al., 2002), NT (8–13) (Banks et al., 1995), PACAP (Banks et al., 1996), SP1–4 and SP3–11 (Freed et al., 2002); while NPY is poor to cross the BBB due to its lack of channels (Li et al., 2019).

Currently, there are several issues that need to be resolved. These issues would require further research into whether these changes in neuropeptide concentrations in CSF or plasma could be used as biomarkers. Additionally, it is needed to explore the potential use of analogs and receptor agonists in clinical trials for PD. Because there are extensive effects of these neuropeptides throughout the body, further studies are also needed to explore the side effects of neuropeptides and their analogs-related drugs in the treatment of PD.

AUTHOR CONTRIBUTIONS

YZ reviewed the literature, drafted, and revised the manuscript. LZ constructed the figures. JX revised the manuscript. LS conceived the study, revised the manuscript and provided funding support. All authors read and approved the final manuscript.

FUNDING

This work was funded by the National Natural Science Foundation of China (31671054 and 31771124), the Postdoctoral Science Foundation of China (2017M610412 and 2018T110666), and Taishan Scholars Construction Project.

REFERENCES

Andrews, Z. B., Erion, D., Beiler, R., Liu, Z. W., Abizaid, A., Zigman, J., et al. (2009). Ghrelin promotes and protects nigrostriatal dopamine function via a UCP2-dependent mitochondrial mechanism. *J. Neurosci.* 29, 14057–14065. doi: 10.1523/JNEUROSCI.3890-09.2009

Antonelli, T., Fuxe, K., Tomasini, M. C., Mazzoni, E., Agnati, L. F., Tanganelli, S., et al. (2007). Neurotensin receptor mechanisms and its modulation of glutamate transmission in the brain: relevance for neurodegenerative diseases and their treatment. *Prog. Neurobiol.* 83, 92–109. doi: 10.1016/j.pneurobio.2007.06.006

Banks, W., Tschöp, M., Robinson, S., and Heiman, M. (2002). Extent and direction of ghrelin transport across the blood-brain barrier is determined by its unique primary structure. *J. Pharmacol. Exp. Ther.* 302, 822–827. doi: 10.1124/jpet.102.034827

Banks, W., Uchida, D., Arimura, A., Somogyvári-Vigh, A., and Shioda, S. (1996). Transport of pituitary adenylate cyclase-activating polypeptide across the blood-brain barrier and the prevention of ischemia-induced death of hippocampal neurons. *Ann. N. Y. Acad. Sci.* 805, 278–277;discussion277–279. doi: 10.1111/j.1749-6632.1996.tb17489.x

Banks, W., Wustrow, D., Cody, W., Davis, M., and Kastin, A. (1995). Permeability of the blood-brain barrier to the neuropeptides8–13 analog NT1. *Brain Res.* 695, 59–63. doi: 10.1016/0006-8993(95)00836-f

Bayliss, J. A., and Andrews, Z. B. (2013). Ghrelin is neuroprotective in Parkinson’s disease: molecular mechanisms of metabolic neuroprotection. *Ther. Adv. Endocrinol. Metab.* 4, 25–36. doi: 10.1177/2042018813479645

Bayliss, J. A., Lemus, M., Santos, V. V., Deo, M., Elsworth, J. D., and Andrews, Z. B. (2016a). Acylated but not des-acyl ghrelin is neuroprotective in an MPTP mouse model of Parkinson’s disease. *J. Neurochem.* 137, 460–471. doi: 10.1111/jnc.13576

Bayliss, J. A., Lemus, M. B., Stark, R., Santos, V. V., Thompson, A., Rees, D. J., et al. (2016b). Ghrelin-AMPK signaling mediates the neuroprotective effects of calorie restriction in Parkinson’s disease. *J. Neurosci.* 36, 3049–3063. doi: 10.1523/JNEUROSCI.4373-15.2016

Brown, D., Tamas, A., Reglodi, D., and Tizabi, Y. (2013). PACAP protects against salsolinol-induced toxicity in dopaminergic SH-SY5Y cells: implication for Parkinson’s disease. *J. Mol. Neurosci.* 50, 600–607. doi: 10.1007/s12031-013-0015-7

Brown, D., Tamas, A., Reglodi, D., and Tizabi, Y. (2014). PACAP protects against inflammatory-mediated toxicity in dopaminergic SH-SY5Y cells: implication for Parkinson’s disease. *Neurotox Res.* 26, 230–239. doi: 10.1007/s12640-014-9468-x

Caberlotto, L., Fuxe, K., and Hurd, Y. L. (2000). Characterization of NPY mRNA-expressing cells in the human brain: co-localization with Y2 but not Y1 mRNA in the cerebral cortex, hippocampus, amygdala, and striatum. *J. Chem. Neuroanat.* 20, 327–337. doi: 10.1016/s0891-0618(00)00107-1

Caberlotto, L., Fuxe, K., Rimland, J. M., Sedvall, G., and Hurd, Y. L. (1998). Regional distribution of neuropeptide Y Y2 receptor messenger RNA in the human post mortem brain. *Neuroscience* 86, 167–178. doi: 10.1016/s0306-4522(98)00039-6

Caberlotto, L., Fuxe, K., Sedvall, G., and Hurd, Y. L. (1997). Localization of neuropeptide Y Y1 mRNA in the human brain: abundant expression in cerebral cortex and striatum. *Eur. J. Neurosci.* 9, 1212–1225. doi: 10.1111/j.1460-9586.1997.tb01476.x

Cannizzaro, C., Tel, B. C., Rose, S., Zeng, B. Y., and Jenner, P. (2003). Increased neuropeptide Y mRNA expression in striatum in Parkinson’s disease. *Brain Res. Mol. Brain Res.* 110, 169–176. doi: 10.1016/s0169-328x(02)00555-7

Carniglia, L., Ramírez, D., Durand, D., Saba, J., Turati, J., Caruso, C., et al. (2017). Neuropeptides and microglial activation in inflammation, pain, and...
neurodegenerative diseases. *Mediators Inflamm.* 2017:5048616. doi: 10.1155/2017/5048616

Carraway, R., and Leeman, S. E. (1973). The isolation of a new hypotensive peptide, neurotensin, from bovine hypothalam. *J. Biol. Chem.* 248, 6854–6861.

Chang, X., Ma, Z., Shi, L., and Xie, J. (2020). Effects of ghrelin on the electrical activities of substantia nigra dopaminergic neurons treated with MPP(+). *Neurochem. Int.* 138, 104780. doi: 10.1016/j.neuint.2020.104780

Chao, O. Y., Wang, A. L., Nikolaus, S., and de Souza Silva, M. A. (2015). NK(3) receptor agonism reinstates tonic order memory in the hemiparkinsonian rat. *Behav. Brain Res.* 285, 208–212. doi: 10.1016/j.bbr.2014.06.006

Chen, X. Y., Du, Y. F., and Chen, L. (2018). Neuropeptides exert neuroprotective effects in Alzheimer's disease. *Front. Mol. Neurosci.* 11:493. doi: 10.3389/fnmol.2018.00493

Chianglia, G., Probst, A., and Palacios, J. M. (1990). Neuropeptins receptors in Parkinson's disease and progressive supranuclear palsy: an autoradiographic study in basal ganglia. *Neuroscience* 39, 351–360. doi: 10.1016/0306-4522(90)90273-7

Chu, J. M., Chen, L. W., Chan, Y. S., and Yung, K. K. (2011). Neuropeptitc effects of neurokinin receptor one in dopaminergic neurons are mediated through Akt/PKB cell signaling pathway. *Neuropharmacology* 59, 1398–1398. doi: 10.1016/j.neuropharm.2011.08.027

Chung, C. Y., Seo, H., Sonntag, K. C., Brooks, A., Lin, L., and Isacson, O. (2005). Distribution of the mRNA for a pituitary adenylate cyclase-activating polypeptide receptor in the rat brain: an in situ hybridization study. *J. Comp. Neurol.* 371, 567–577. doi: 10.1002/sin.96199605371: 4-576:AID-CNE6-3.0.CO;2-2

Hou, Z., Miao, Y., Gao, L., Pan, H., and Zhu, S. (2006). Ghrelin-containing neuron in cerebral cortex and hypothalamus linked with the DVC of brainstem in rat. *Regul. Pept.* 134, 126–131. doi: 10.1016/j.regpep.2006.02.005

Jiang, H., Li, L. J., Wang, J., and Xie, J. X. (2008). Ghrelin antagonizes MPTP-induced neurotoxicity to the dopaminergic neurons in mouse substantia nigra. *Exp. Neurol.* 212, 532–537. doi: 10.1016/j.expneurol.2008.05.006

Jiao, Q., Du, X., Li, Y., Gong, B., Shi, L., Tang, T., et al. (2017). The neurological effects of ghrelin in brain diseases: beyond metabolic functions. *Neurosci. Biobehav. Rev.* 73, 98–111. doi: 10.1016/j.neubiorev.2016.12.010

Jomphê, C., Lemelin, P. L., Okano, H., Kobayashi, K., and Trudeau, L. E. (2006). Bidirectional regulation of dopamine D2 and neurotensin NTS1 receptors in dopamine neurons. *Eur. J. Neurosci.* 24, 2789–2800. doi: 10.1111/j.1460-9586.2006.05151.x

Kanazawa, I., and Jessell, T. (1976). Post mortem changes and regional distribution of substance P in the rat and mouse nervous system. *Brain Res.* 117, 362–367. doi: 10.1016/0006-8993(76)90748-4

Kerkerian, L., Bosler, O., Pelletier, G., and Nieoullon, A. (1986). Striatal neuropeptide Y system in the future treatment of Parkinson's disease. *Neuropharmacology* 25, 208–212. doi: 10.1016/0306-4522(88)90091-4

Kerkerian, L., Bosler, O., Pelletier, G., and Nieoullon, A. (1986). Striatal neuropeptide Y system in the future treatment of Parkinson's disease. *Neuropharmacology* 25, 208–212. doi: 10.1016/0306-4522(88)90091-4

Kim, W., Mohney, R., Wilson, B., Jeon, G., Liu, B., and Hong, J. (2000). Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia. *J. Neurosci.* 20, 6309–6316. doi: 10.1523/jneurosci.20-16-06309.2000

Kojima, M., Hosoda, H., Date, Y., Nakazato, M., Matsu, H., and Kangawa, K. (1999). Ghrelin is a growth-hormone-releasing acylated peptide from stomach. *Nature* 402, 656–660. doi: 10.1038/45230

Kornkrez, O., and Tuncel, N. (2018). Advantages of vasoactive intestinal peptide for the future treatment of Parkinson's disease. *Curr. Pharm. Des.* 24, 4693–4701. doi: 10.2174/138162242018240421901110593

Fernandez, A., de Ceballos, M. L., Jaffer, P., and Marsden, C. D. (1995). Characterization of neuropeptin-like immunoreactivity in human basal ganglia: increased neuropeptin levels in substantia nigra in Parkinson's disease. *Peptides* 16, 339–346. doi: 10.1016/0191-9914(94)90141-3

Ferreira, R., Xapelli, S., Santos, T., Silva, A. P., Cristovao, A., Cortes, L., et al. (2010). Neuropeptide Y modulation of interleukin-1-beta (IL-1-beta)-induced nitric oxide production in microglia. *J. Biol. Chem.* 285, 41921–41934. doi: 10.1074/jbc.M110.164020

Freed, A., Audus, K., and Lunte, S. J. P. (2002). Investigation of substance P transport across the blood-brain barrier. *Peptides* 23, 157–165. doi: 10.1016/s0196-9817(01)00592-7

Fumagalli, F., Racagni, G., and Riva, M. A. (2006). Shedding light into the role of BDNF in the pharmacotherapy of Parkinson's disease. *Pharmacogenomics* 7, 95–104. doi: 10.1083/jtp.6500360

Ferreira, R., Xapelli, S., Santos, T., Silva, A. P., Cristovao, A., Cortes, L., et al. (2010). Neuropeptide Y modulation of interleukin-1-beta (IL-1-beta)-induced nitric oxide production in microglia. *J. Biol. Chem.* 285, 41921–41934. doi: 10.1074/jbc.M110.164020

Frontiers in Aging Neuroscience | www.frontiersin.org

9 March 2021 | Volume 13 | Article 646726
substance P, and vasoactive intestinal peptide in parkinsonian adrenal medulla. *Exp. Neurol.* 114, 23–27. doi: 10.1016/0014-4886(91)90080-v

Suda, Y., Kuzumaki, N., Sone, T., Narita, M., Tanaka, K., Hamada, Y., et al. (2018). Down-regulation of ghrelin receptors on dopaminergic neurons in the substantia nigra contributes to Parkinson's disease-like motor dysfunction. *Mol. Brain* 11.6. doi: 10.1186/s13041-018-0349-8

Svenningsson, P., Palhagen, S., and Mathé, A. A. (2017). Neuropeptide Y and calcitonin gene-related peptide in cerebrospinal fluid in Parkinson's disease with comorbid depression versus patients with major depressive disorder. *Front. Psychiatry* 8:102. doi: 10.3389/fpsyt.2017.00102

Tatemoto, K. (1982). Neuropeptide Y: complete amino acid sequence of the brain peptide. *Proc. Natl. Acad. Sci. U.S.A.* 79, 5485–5489. doi: 10.1073/pnas.79.18.5485

Tenovuo, O., Rinne, U. K., and Viljanen, M. K. (1984). Substance P immunoreactivity in the post-mortem parkinsonian brain. *Brain Res.* 303, 113–116. doi: 10.1016/0006-8993(84)90217-8

Thornton, E., Hassall, M. M., Corrigan, F., and Vink, R. (2014). The NK1 receptor antagonist N-acetyl-L-tryptophan reduces dyskinesia in a hemi-parkinsonian rodent model. *Parkinsonism Relat. Disord.* 20, 508–513. doi: 10.1016/j.parkreldis.2014.02.008

Thornton, E., and Vink, R. (2012). Treatment with a substance P receptor antagonist is neuroprotective in the intrastriatal 6-hydroxydopamine model of early Parkinson's disease. *PLoS One* 7:e34138. doi: 10.1371/journal.pone.0034138

Tuncel, N., Korkmaz, O., Tekin, N., Şener, E., Akıyüz, F., and Inal, M. (2012). Antiapoptotic and anti-apoptotic activity of vasoactive intestinal peptide (VIP) against 6-hydroxy dopamine toxicity in the rat corpus striatum. *J. Mol. Neurosci.* 46, 51–57. doi: 10.1007/s12031-011-9618-z

Tuncel, N., Şener, E., Cerit, C., Karasu, U., Güner, F., Sahintürk, V., et al. (2005). Brain mast cells and therapeutic potential of vasoactive intestinal peptide in a Parkinson's disease model in rats: brain microdialysis, behavior, and microcopy. *Peptides* 26, 827–836. doi: 10.1016/j.peptides.2004.12.019

Uhl, G. R., Whitehouse, P. J., Price, D. L., Tourtellotte, W. W., and Kuhar, M. J. (1984). Parkinson's disease: depletion of substantia nigra neurotensin receptors. *Brain Res.* 308, 186–190. doi: 10.1016/0006-8993(84)90935-1

Vaudry, D., Falluel-Morel, A., Bourgault, S., Basille, M., Burel, D., Wurtz, O., et al. (2009). Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 anticancer and anti-apoptotic activity of vasoactive intestinal peptide (VIP) against 6-hydroxy dopamine toxicity in the rat corpus striatum. *J. Mol. Neurosci.* 46, 51–57. doi: 10.1007/s12031-011-9618-z

Vincent, J. P., Mazella, J., and Kitabgi, P. (1999). Neurotensin and neurotensin receptors. *Trends Pharmacol. Sci.* 20, 302–309. doi: 10.1016/s0165-6147(99)01357-7

Wagner, I., Vulinovic, F., Gruenewald, A., Unger, M. M., Moller, J. C., Klein, C., et al. (2017). Acylated and unacylated ghrelin confer neuroprotection to mesencephalic neurons. *Neuroscience* 365, 137–145. doi: 10.1016/j.neuroscience.2017.09.045

Wang, G., Pan, J., Tan, Y. Y., Sun, X. K., Zhang, Y. F., Zhou, H. Y., et al. (2008). Neuroprotective effects of PACAP27 in mice model of Parkinson's disease involved in the modulation of K(ATP) subunits and D2 receptors in the striatum. *Neuropptides* 42, 267–276. doi: 10.1016/j.npep.2008.03.002

Wang, G., Qi, C., Fan, G. H., Zhou, H. Y., and Chen, S. D. (2005). PACAP protects neuronal differentiated PC12 cells against the neurotoxicity induced by a mitochondrial complex I inhibitor, rotenone. *FEBS Lett.* 579, 4005–4011. doi: 10.1016/j.febslet.2005.06.013

Wang, Q., Chu, C. H., Qian, L., Chen, S. H., Wilson, B., Oyarzabal, E., et al. (2014). Substance P exacerbates dopaminergic neurodegeneration through neurokinin-1 receptor-independent activation of microglial NADPH oxidase. *J. Neurosci.* 34, 12490–12503. doi: 10.1523/JNEUROSCI.2238-14.2014

Wang, Q., Oyarzabal, E., Wilson, B., Qian, L., and Hong, J. S. (2015a). Substance P enhances microglial density in the substantia nigra through neurokinin-1 receptor/NADPH oxidase-mediated chemotaxis in mice. *Clin. Sci. (Lond)* 129, 757–767. doi: 10.1042/CS20150008

Wang, S. Y., Chen, L., Xue, Y., and Xia, Y. J. (2015b). Substance P prevents 1-methyl-4-phenylpyridinium-induced cytotoxicity through inhibition of apoptosis via neurokinin-1 receptors in MES23.5 cells. *Med. Mol. Rep.* 12, 8085–8092. doi: 10.3892/mmr.2015.4464

Xue, B., Li, C., Chang, X., Jiang, H., Shi, L., and Xie, J. (2020). Ghrelin reduces A-type potassium currents in dopaminergic nigral neurons via the PLC/PKCdelta pathway. *Neurosci. Bull.* 36, 947–950. doi: 10.1007/s12264-020-00508-4

Yamada, M., Yamada, M., and Richelson, E. (1995). Heterogeneity of melanized neurons expressing neurotensin receptor messenger RNA in the substantia nigra and the nucleus paragigralis of control and Parkinson's disease brain. *Neuroscience* 64, 405–417. doi: 10.1016/0306-4522(94)00395-1

Yan, H., Yang, J., Marasco, J., Yamaguchi, K., Brenner, S., Collins, F., et al. (1996). Cloning and functional expression of cDNAs encoding human and rat pancreatic polypeptide receptors. *Proc. Natl. Acad. Sci. U.S.A.* 93, 4661–4665. doi: 10.1073/pnas.93.10.4661

Yang, S., Yang, J., Yang, Z., Chen, P., Fraser, A., Zhang, W., et al. (2006). Pituitary adenylate cyclase-activating polypeptide (PACAP) 38 and PACAP4-6 are neuroprotective through inhibition of NADPH oxidase: potent regulators of microglia-mediated oxidative stress. *J. Pharmacol. Exp. Ther.* 319, 595–603. doi: 10.1124/tp.106.102236

Yang, X., Zhao, H., Shi, H., Wang, X., Zhang, S., Zhang, Z., et al. (2015). Intraneuronal administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease. *Exp. Neurol.* 271, 168–174. doi: 10.1016/j.expneurol.2015.05.007

Yu, J., Xu, H., Shen, X., and Jiang, H. (2016). Ghrelin protects MES23.5 cells against rotenone via inhibiting mitochondrial dysfunction and apoptosis. *Neuropeptides* 56, 69–74. doi: 10.1016/j.npep.2015.09.011

Yu, R., Li, J., Lin, Z., Ouyang, Z., Huang, X., Reglodi, D., et al. (2020). TAT-tagging of VIP exerts positive allosteric modulation of the PAC1 receptor and enhances VIP neuroprotective effect in the MPTP mouse model of Parkinson's disease. *Biochim. Biophys. Acta Gen. Subj.* 1864:129626. doi: 10.1016/j.bbagen.2020.129626

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.